Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K....
-
Upload
elmer-carroll -
Category
Documents
-
view
212 -
download
0
Transcript of Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K....
![Page 1: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/1.jpg)
Developing Risk Management Systems that meet FDA rules ---
and don’t hurt your product
Judith K. JonesPresident, The Degge Group, Ltd.
Louis A. Morris President , Louis A. Morris & Associates
Gina AsheVP Marketing, Infomedics
![Page 2: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/2.jpg)
articipants should appreciate strategic and tactical elements for developing a Risk Management (RM) Plan:– Risk Assessment
• Natural History of Disease
– Developing a RM Strategy• Designing Distribution control• Developing Communication Objectives
– Designing a RM Program• Behavioral Goals and Objectives• Selecting and Justifying Tools• PreTesting Communications• Planning Evaluation
Objectives
![Page 3: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/3.jpg)
FORMAT: PROBLEM SOLVING EXERCISE
• Introductions, Background & Goals for Today– (15 minutes)
• Form Groups– 8:45-10 AM: Developing a RM Strategy
• Problem Identification• Understand Risk Assessment Issues (by example)• Defining Desired Behavioral Outcomes, Communications,
Distribution Controls
– 10-10:20 AM: Break– 10:20-11:20: Developing the FDA RM Plan
• Goals, Objectives, Tools,, Evaluation Planning
– 11:20-12:00 Group Presentations and commentary by Audience and Faculty
![Page 4: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/4.jpg)
BackgroundFDA: Need to Develop a RM Plan
![Page 5: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/5.jpg)
![Page 6: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/6.jpg)
Recent Withdrawals• Seldane (terfenadine) 2/98
• Posicor (mibefradil) 6/98
• Duract (bromphenac) 6/98
• Hismanal (astemizole) 6/99
• Roxar (grepafloxacin) 11/99
• Propulsid (cisapride) 3/23/00
• Rezulin (troglitazone) 3/21/00
• Lotronex (alosetron HCl) 8/24/00
• Raplon (rapcuronium) 3/01
• Baycol (cerivaxtatin) 8/8/01
92 NME’s from 1998-2000
![Page 7: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/7.jpg)
Rezulin Withdrawal
“FDA took this action after its review of recent safety data…showed that Rezulin is more toxic to the liver than the other two drugs” [HHS News, 3/21/00]
“And we’ve had to withdraw drugs from the market that would have been safe if used according to label instructions” [Janet Woodcock, Temple University, 4/4/00]
![Page 8: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/8.jpg)
AUG 09, 2001
Anticholesterol Drug Pulled After Link to 31 Deaths
With Baycol, however, reports of serious rhabdomyolysis were about 10 times as frequent as with the other statins, Dr. Jenkins said.
"Baycol really stood out as being different," he said. "Baycol did not offer any benefits beyond those of the other statins. But it carried a potential risk, and that leads to a conclusion that it is no longer safe to be marketed."
![Page 9: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/9.jpg)
Import Alerts- drugs with RM plans
Examples of Drugs with RM Controls
• Accutane (isotretinoin) - severe recalcitrant nodular acne • Actiq (fentanyl citrate) - severe cancer pain • Clozaril (clozapine) - severe schizophrenia• Lotronex (alosetron hydrochloride)
- severe irritable bowel syndrome in women • Mifiprex (mifepristone or
RU-486) - termination of early intrauterine pregnancy • Thalomid (thalidomide) - erythema nodosum leprosum • Tikosyn (dofetilide) - maintenance of normal sinus rhythm • Tracleer (bosentan) - severe pulmonary arterial hypertension • Trovan (trovafloxacin
mesylate or alatrofloxacin mesylate injection) - severe, life-threatening infections
• Xyrem (sodium oxybate) - narcolepsy
![Page 10: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/10.jpg)
Top 20
![Page 11: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/11.jpg)
FDA RM Guidances
• Concept Papers Released March 3, 2003• Hearings April 9 – 11, 2003• Three Papers:
– Premarketing Risk Assessment
– Risk Management Programs
– Risk Assessment of Observational Data: Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment
• Guidances To Be Finalized September, 2004
![Page 12: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/12.jpg)
Risk Management Guidance
• Sponsor proposes a Risk Management Program (RMP)– Background and rationale for RM approach– Goals, Objectives and RMP Level (4 levels)– Tools and Implementation plan for each tool– Evaluation Plan for each tool and for the
overall RMP• Analyses to be conducted• Reporting results to FDA
Risk Management is the process of minimizing risks throughout a product’s lifecycle to optimize the benefit/risk balance
![Page 13: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/13.jpg)
The Four Levels of Risk Management
• Level 1 Package Insert only
• Level 2 Level 1 + education and outreach to health professionals and
patients/consumers
• Level 3 Level 2 + systems that guide the prescribing, dispensing, or receipt of a product
• Level 4 Level 3 + Access to product requires
adherence to program elements
Levels may go – concept of progressive interventions will stay
![Page 14: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/14.jpg)
Risk Management
Known RisksUnknown Risks
•Discovering and interpreting safety signals
•Phase IV Commitments
•Do I need a study/registry?
•Designing interventions (tools)
•Justifying choice of interventions
•Pre-testing Interventions
•Implementing interventions
•Evaluating interventions
•Revising interventions
![Page 15: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/15.jpg)
Risk Management Irony
Perception of Risk
Willing-ness to
Use
Safety =Benefits
RisksBeliefs Perceptions
Unintended Consequences
![Page 16: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/16.jpg)
Four Pillars ofRisk Management
•Risk Assessment
•Signal Evaluation
•Risk Communication
•System Controls
![Page 17: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/17.jpg)
Forming Groups:Fair Distribution of Disciplines
Reseat if necessaryAppoint Leader/Recorder/Reporter
![Page 18: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/18.jpg)
Product #1• A product for diabetic neuropathy shown to
be very effective causes severe tachycardia (rapid heart rate) with excess caffeine in a genetically sensitive group.
• This group can be identified by a genetic test which is costly (~$3000/person)
• The drug’s profile is otherwise benign
![Page 19: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/19.jpg)
Product # 2
• An antibiotic product indicated for upper respiratory infections is highly effective with most pathogens, including resistant organisms-likely to be used widely.
• Its risk is similar to other antibiotics except that if used more than twice in a three month period, it causes severe diarrhea and colitis, particularly toxic to the elderly and children.
![Page 20: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/20.jpg)
Tasks for Groups• 8:45-10:00• Identify and Define
1. Additional Study• Conduct a phase IV study to help identify and characterize
the risk (30 min)
2. Developing a RM Strategy• Who, What, How, When, Where and Why? (20 min)
3. How to manage Risks?• List Key Messages (selected) for each audience (10 min)• Assume that FDA believes that communications by
themselves will be insufficient. What distribution system controls will be necessary to influence desired behaviors? (15 min)
![Page 21: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/21.jpg)
Phase IV Study
• Who will we recruit?– Types of people (assume statisticians
estimate that at least 2000 people are needed)
• How will we recruit them?
• What will we measure?– Conceptually, what do we need to know?– How will we measure it?
![Page 22: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/22.jpg)
Task: RM Strategy
1. Define the problem– What are the specific risk we are facing in terms of what
can happen to which patients under what conditions?2. Develop the overall RM Strategy:
1. Who do we need to influence?2. What do we want them to do? (Be specific, define for each
audience)3. When/Where do they need to exhibit this behavior
(conditions)4. How will we get them to do it?
What messages will be necessary to influence behavior Will “information” be sufficient? Do we need “behavioral control systems”?
![Page 23: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/23.jpg)
BackgroundRisk Communications and
Behavioral/Distribution Controls
![Page 24: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/24.jpg)
Part ICommunications
![Page 25: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/25.jpg)
Communications Planning
• What to do people need to know?– Message must be sufficient to influence behavior
• Must affect Knowledge– Be Understood– May need to motivate audience (personal susceptibility, willingness to
overcome barriers to resistance, motivate behavior)• Will “information” be sufficient? Do we need “behavioral control
systems”?
• How to communicate it?– What are the key primary and secondary messages? (Communication
Objectives)– What media will reach intended audience (how much redundancy)?– Will we need a Medication Guide?
• How do I know it is working? (next session)– Pretesting– Evaluation Planning
![Page 26: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/26.jpg)
Developing Communication Objectives (COs)
• What is the most important information for people to know about using this drug?– List in descending order of importance– Assume must provide information relevant to six headers
for MedGuides if preparing most patient information documents
• What do we need to say to influence advocated behavior?
• List for each audience
![Page 27: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/27.jpg)
Information Options
• HCPs– PI, Label Changes (black box), Dear Doctor letters,
Advertisements (medication errors), Fair Balance in ads, MedEd, brochures, etc.
• Patients – PPIs, Medication Guide, Informed Consent, Multiple
options (Accutane, Thalidomide), refrain from DTC.• Public (PR)
– FDA public announcements (talk papers, press releases), website posting, advisory committee meetings
![Page 28: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/28.jpg)
Communications Process
• Exposure Distribution• Attention Readership• Interest Willingness to Read• Understand Comprehension• Accept Attitude Change• Memory Recall/Recognition Tests• Decide Decision Making Scenarios • Behave Intention to Heed/Behavior• Learn Behavior Maintenance
Goal/Barrier Measure
Select Vehicles to Maximize Communication Goal May need a combination of Vehicles
![Page 29: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/29.jpg)
Risk Communications (1)
• Seek Intervention that will force exposure– PPI – voluntary distribution (7% for Darvon)
– MG – required by law (39% for Estrogen PPI)
– Packaging – systems (93% for OCs)
• Risk Messages break through clutter– Clearly identify as risk message (not marketing in
disguise)
• Redundancy for backup and reminder purpose (not as primary communication purpose)
![Page 30: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/30.jpg)
Risk Communications (2)
• Assure Understanding of Key Objectives– Will not get sufficient repetition– Test for COs in Comprehension Tests
• Understand Factors Controlling Behavior Change– Attitude-Behavior Consistency– Barriers as well as Facilitators
• Evaluation Specific Enough to Understand Failures and Recommend Changes
![Page 31: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/31.jpg)
Part IIImplementing and Evaluating An
RM Program
![Page 32: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/32.jpg)
Message Development
Message Development
B/RM Planning & DesignB/RM Planning & Design
Research/ Testing
Research/ Testing
SystemsDesign
SystemsDesign
B/RM ImplementationB/RM Implementation
RM System Design
EvaluationEvaluation
![Page 33: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/33.jpg)
Distributional Controls
Closed System
Prior Approvals
CertificationSpecial Packaging
Record Keeping
Controlled Substances
Actiq Fosamax
Tikosyn Thalomid Accutane
Clozaril
How do we slot the risk-control level for any drug?
![Page 34: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/34.jpg)
Doctor
PatientMultiplatform
Delivered Tests
SafetyAssessmentPeriodic
MD or PatientRegistersPatient
Co
mp
ilatio
n &
Re
po
rting
Patient Education
& Feedback
RM Evaluation
Patient Experience Feedback
MD Intervention
Iterative
Multi-Function Registry
![Page 35: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/35.jpg)
Part IIIBehavioral Outcomes
![Page 36: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/36.jpg)
Sample of Desired Behaviors• MDs
– Select appropriate patients– Provide RM counseling patients– Oversee compliance with necessary behaviors (lab tests)– Side Effect monitoring
• Patients– Understand medication’s risks– Understand avoidance behaviors
• behaviors necessary to prevent risks
– Behavioral Compliance • Initiating and maintaining behaviors with medication taking requirements to
avoid adverse events
May need iterative education and motivation
![Page 37: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/37.jpg)
“Practicalities” of Engaging MDs
• MD time constraints• The office staff “shield”• Limitations of Distribution channels
– Sales Rep as the RM messenger– The clutter of direct mail– Technology limitations
• Attitudes toward adopting new (potentially risky) medications into their practice
• General risk aversion (on several fronts)
![Page 38: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/38.jpg)
Avoid “One Size Fits All” Approach to MDs
• Specialists vs. PCPs• Targeting the “right” physicians early in the
program (sissy vs. sassy docs)• KOL acceptance• For those interested in the Medicine:
– This is an issue of patient safety– This may be a particular necessary medicine– Prescribers need to know this
![Page 39: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/39.jpg)
The MD Comfort Zone
Will benefit and protect patient,Willing to try
Too Much RM
Too Little RM
Comfort Zone
Personal Liability
Too much work to use
Drug may hurt patient
Too risky to try
![Page 40: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/40.jpg)
Consider Providing Patient Feedback to Their MDs
• Additional knowledge MDs gain about:– patient comprehension of product benefits and risks
– Benefit/Risk Perceptions
– Barriers to Use
– Attitudes about Medication
– Motivations
– Behavioral Intentions
– Compliance Measures
![Page 41: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/41.jpg)
0%10%20%30%40%50%60%70%80%90%
100%
0 1 2 3 4 5 6
Months Since Starting Therapy
% S
till
on
Th
erap
y Baseline*
Breakeven**
Statin+
Program++
Patient Compliance Insight #1: Information is Not Learning
*Scott-Levin data 10/00-3/01 showing 45% of patients continuing on medication each month from prior month.**Internal calculations using program costs, expected returns, and Scott-Levin Rx data.+Scott-Levin data from 10/00-3/01 for monthly adherence of statin users. ++Adherence rates observed among Adhere program participants.
71%
Example of Cholesterol-Lowering Medication
![Page 42: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/42.jpg)
Patient Compliance Insight #2:Physicians’ Active Role is Essential
• Driven by physician-patient relationship
• Deliberate “ask” from MD
• Patients increasingly turning to their own sources for information, may be unreliable
InfoMedics Survey: Why Do Patients Comply with Programs?
• 73% of patients motivated to participate because of doctor-patient relationship
• 80% of patients would participate again if asked by physician
![Page 43: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/43.jpg)
Patient Compliance Insight #3:Each patient conducts their own
individual “risk assessment”• Medication containing estrogen, topically applied
for short periods of time only, shown to not enter blood stream
• MDs comfortable with remote risk of breast cancer (no documented cases)
• MDs recognized significant symptom relief and quality of life improvements that medication delivered
• Patient concerns around “HRT therapies” caused MDs concerns--not willing to prescribe
![Page 44: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/44.jpg)
Tasks for Groups-2• 10:20-11:30 • Design:
1. RMP Outline• Goals, Objectives• Choice of Tools and Justification (30 min)
2. Methods of Evaluation:• Individual Tools (Comprehension Test)
– List Communication Objectives
• The Risk Management Plan (30 min)
These tasks should be completed for presentation
![Page 45: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/45.jpg)
BackgroundFDA Concept Paper
![Page 46: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/46.jpg)
RM Concept Paper
• Risk Management Program– A strategic program designed to decrease
product risk by using one or more interventions or tools beyond the PI. For example:
• Specialized educational materials
• Processes or forms to increase compliance or reduce risk
• Systems to modify prescribing, dispensing and use
![Page 47: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/47.jpg)
RM Program
• RM Goals and Objectives– RM Program should have one or more safety
related goals…tailored to specific concerns– Goals are broad, conceptual statements of
desired outcomes– Objectives are translation of goals into
pragmatic, specific and measurable processes or behavioral outcomes
• Apply to each audience
![Page 48: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/48.jpg)
Part IITool Selection
![Page 49: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/49.jpg)
Form (tools) Distribution PurposeBrochure Physician General Education
PPI Package or Pharmacist Broad Risk Communication
Medication Guide Package Risk Communication and Methods of Avoidance
Informed Consent Physician Acknowledgement of Risks
Warning on Package Package Risk “signal”/compliance reminder
Wallet Card Starter Kit Reminder
Stickers: Medication Vial or Prescription
Medication Vial or Prescription
Reminder or time sensitive controls
Patient Agreement or Contract
Physician Behavioral Commitment
Decision Aid Physician Choice of Therapy
Video Tape or CD Physician or Starter Kit Persuasion or Choice of Therapy
Recurring Interventions (telephone calls)
Telephone Behavioral Maintenance
![Page 50: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/50.jpg)
Sample Tactics Matrix GoalAudience
Awareness Motivation Reinforcement
Sales Detail Aid Training manual Leave behinds
CRM Affirmative Scripts, Q&As
Training video Desk Top Media
MDs Mailing Sales Rep Material Desk Top Media, poster
ER Sales force materials
Grand Rounds Training
Poster
Patients/Partners
Waiting room placard, pharmacy printouts
Brochure/Web site, MD materials
Materials with logo
Theme: Risk Avoidance Involvement Logo as ReminderTheme: Risk Avoidance Involvement Logo as Reminder
![Page 51: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/51.jpg)
When is a Medication Guide Needed?
• When product poses a “serious and significant public health concern ...”
• Translated: when patient information is necessary to safe and effective use
• To apply to between 5 and 10 products (drugs and biologics) annually
• Not to be used indiscriminately
Adapted from Ostrove, 2001
![Page 52: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/52.jpg)
Triggering Circumstances (201.8)
• Could help prevent serious adverse effects
• When patient needs to know of serious risks, relative to benefits, that might affect decision to use or continue use
• When drug is important to health, and patient adherence to directions is crucial to effectiveness
Adapted from Ostrove, 2001
![Page 53: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/53.jpg)
Six Headers That Patients Need to Know (Adapted Slightly)
• What is the most important information I should know?
• What does “Drug” do?• Who should not take “Drug”?• How should I take “Drug”?• What should I avoid while taking “Drug”?• What are the possible or reasonably likely
side effects?FDA on its initiative…may exempt or defer any MG content or
format requirement on the basis that it is inapplicable, unnecessary or contrary to patients’ best interest
![Page 54: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/54.jpg)
Tools Selection
• Necessary And Sufficient for Influencing Behavior
• FDA: Selecting Tools– Input from stakeholders– Consistency with existing tools– Documented evidence– Degree of validity and reproducibility
![Page 55: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/55.jpg)
Tools Selection-Suggestions
• Have a conceptual model– What is necessary to influence behavior
• Type of Behavior (short term or long term)
• Reliance on Memory (recall or environmental cues)
• Use Clinical/Marketing Data– Describe audience
• Demographically and psychographically (motivations)
• Justification– Select sufficient/diverse tools to “solve problem”
![Page 56: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/56.jpg)
How Many/What Type of Tools?
• Just Enough– Too Little RM
• FDA perception that company “doesn’t get it”
• Physicians unwilling to prescribe (lack of comfort)
– Too Much RM can cause a “backlash” • Unintended Consequences (failure to prescribe
because of RM obligations)
![Page 57: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/57.jpg)
Part IIIPre-Testing and Evaluation
![Page 58: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/58.jpg)
Comprehension Tests• Need to Test to Determine Understandability
– Potential to effect behavioral change– May help with Document Simplification
• but not leave out meaningful details
• Enhance Liability Protection – Defense against failure to warn
• Common for Rx to OTC Switches• Applied to Medication Guides
– Informed Consent, Brochures, Videos, etc.• Applied to Physician Labels• Evolving to test decision making, attitudes, intentions
![Page 59: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/59.jpg)
Testing Considerations• Do we need actual patients?
– May require Clinic Study or screening?• Can we generalize from non-patients?• Are experienced patients too knowledgeable?
– Important subpopulations (low literacy, younger)
• What documents need to be tested?– Key (Core) Communication Vehicles– Testing in what combination – may need field test
• What do we want to know from the tests?• Document diagnostics
– Suggestions for improvements
• Meet Benchmarks – 80% to 85% for primary COs• RM document longer and more complex, need secondary COs
![Page 60: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/60.jpg)
General Procedure
• Recruit (n= 400 to 1,200)– Use Shopping Malls/Clinical Trials/Patients– Screen for at-risk population
• Disease characteristics
• Low Literacy (pronunciation tests)
• Design– One Cell Survey– Multi-Cell Comparisons
![Page 61: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/61.jpg)
General Procedure (2)
• Procedure– Screening– Document Exposure – read as normally would
• Interviewer Leaves Room
• Questionnaire– Develop Communication Objectives– Funnel Approach
– Open ends– Specific Communication Objectives– Follow-up Questions
– Document usually present (may be taken away for initial open ends)
![Page 62: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/62.jpg)
Evaluation
• How can we know the impact of our RM interventions?– Seek behavior change/adherence
• If we do not get “sufficient” adherence:– Can we “diagnose” the failure?
– Will we be able to revise the plan?
– What do we mean by “sufficient” anyway?• Benchmarks or evaluation criteria
• Do we need to set these levels a priori?
![Page 63: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/63.jpg)
Risk Management Concept Paper
• Evaluation of RM Tools– Select well-defined, validated metrics– Use at least 2 different evaluation methods for
key objectives or goals– Use qualitative data … when quantitative data
are not available or not applicable– Consider using evaluation methods for each
RM tool.
![Page 64: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/64.jpg)
Evaluation of Goals & Objectives
• Evaluation must match specific goals/objectives– Education – measure comprehension, opinions, etc.
• Education encompasses knowledge, persuasion, decision making, etc• For example: Detect occurrence of MAADO
– Behavior Change – measure by observation & self-report– Limited Use - drug use data base– Reduce ADRs – collect ADR experience
• Can we use spontaneous reports?
• Data Collection Methods– Questionnaires (multiple sampling methods)– Existing database (administrative, prescribing)
• Evaluate Tools pre and/or post launch• Evaluate “unintended consequences”
![Page 65: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/65.jpg)
Bi-Directional Evaluation
RMP
Survey
Database
Measure Behavioral Impacts
Measure, knowledge, beliefs, intentions, reported behavior
![Page 66: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/66.jpg)
Existing Databases
• Numerous Available– Each has strengths and weaknesses
• Some focus on claims (have diagnosis and outcomes)
• Some focus on prescribing
• Some focus ER visits
– May be able to use surrogate indicators
• Limits on explanatory variables
![Page 67: Developing Risk Management Systems that meet FDA rules --- and don’t hurt your product Judith K. Jones President, The Degge Group, Ltd. Louis A. Morris.](https://reader030.fdocuments.in/reader030/viewer/2022032802/56649e1a5503460f94b07eab/html5/thumbnails/67.jpg)
RM Survey Sampling Methodology
• Registry– Theoretically an audit, in reality – low response rate– Time Series (surveys)
• Concern about prior surveys biasing response• Concern about running out of sample
• Consider– Probability sampling (smaller but scientific sample)
• Response rates are in the basement toilet
– Bell-Weather (Sentinel Cites) or Quota sampling • smaller, incentivized sample
– Multifunction Registry • integrate marketing and safety purposes
– Geographical Testing• Base program for all, add-ons tested for impact